Deborah Levine, MD
Pulmonary Disease · Stanford, CANPI 1831206804
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Insmed, Inc. at 47.2% of the total. Reporting peaked in 2019 at $68,911 and has fallen 94.2% since, to $3,992 in 2025. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 214 payments — averaging $776.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$78K
- Actelion Pharmaceuticals US, Inc.$28K
- Zambon USA Ltd.$26K
- Merck$14K
- United Therapeutics Corporation$9K
- One Lambda, Inc.$3K
- plus $8K from 9 others
Across 18 payments — averaging $3611.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$51K
- Actelion Pharmaceuticals, Ltd$11K
- Biotest AG$3K
What the payments were for
- Consulting fees$57,02534%
- Speaking & faculty fees$72,56844%
- Travel & lodging$32,03819%
- Food & beverage$4,5143%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 118 | $78,479 |
| Actelion Pharmaceuticals US, Inc. | 10 | $28,145 |
| Zambon USA Ltd. | 33 | $26,333 |
| Merck | 8 | $13,571 |
| United Therapeutics Corporation | 23 | $8,825 |
| One Lambda, Inc. | 4 | $3,162 |
| Kamada Ltd. | 4 | $2,706 |
| GSK | 1 | $2,000 |
| Sanofi-aventis U.S. LLC | 3 | $1,276 |
| Pierre Fabre Pharmaceuticals, Inc. | 2 | $602 |
| Vertex | 1 | $492 |
| Paragonix Technologies, Inc. | 4 | $282 |
| AstraZeneca | 1 | $150 |
| Therakos LLC | 1 | $92 |
| La Jolla Pharmaceutical Company | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$166,148 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CresembaIsavuconazonium Sulfate | 24 | $147,776 |
| PrevymisLetermovir | 12 | $95,910 |
| Posaconazole | 60 | $65,252 |
| Everolimus | 20 | $24,602 |
| Itraconazole | 53 | $22,601 |
| EliquisApixaban | 25 | $19,976 |
| Valganciclovir Hcl | 78 | $13,145 |
| Atovaquone | 24 | $10,834 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,544 |
| Tacrolimus | 58 | $4,887 |
| Advair DiskusFluticasone Propion/Salmeterol | 12 | $2,362 |
| SpsSodium Polystyrene Sulfon/Sorb | 12 | $1,665 |
| Mycophenolate Mofetil | 26 | $1,547 |
| Acyclovir | 81 | $1,050 |
| Ventolin HfaAlbuterol Sulfate | 14 | $682 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckPrevymis | $13,571 | $95,91012 claims |
| GSKBreo Ellipta | $2,000 | $6,54417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Stanford
- Revati ShreeniwasStanford$726K
- Roham ZamanianStanford$86K
- Brian ShallerStanford$82K
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- David PhamWestminster$571K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.